Nautilus Biotechnolgy, Inc. Common Stock (NAUT)
Nautilus Biotechnologies, Inc. is a biotechnology company focused on developing advanced platform technologies for protein analysis and drug discovery. The company aims to revolutionize the understanding of complex biological systems by providing highly detailed insights into proteins, which are crucial for understanding disease mechanisms and developing new therapies.
Company News
Nautilus Biotechnology (NAUT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2024.
U.S. stocks traded lower, with the Dow Jones falling around 100 points on Monday. Here are some big stocks recording gains in today’s session. Canopy Growth Corporation (NASDAQ: CGC) shares gained 12.5% to $0.9422. ESS Tech, Inc. (NYSE: GWH) shares jumped 10.1% to $1.53. Honeywell International Inc (NASDAQ: HON) entered into a strategic col...
Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week.
Penny stocks to watch right now. The post 3 Penny Stocks Under $3 To Watch In March appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.